Establishment of a national on-line registry for apheresis in Korea

Song, Eun Young; Yoon, Jong Hyun; Lee, Jong Wook; Park, Chong Won; Kwon, Seog Woon; Kim, Dae Won; Lim, Young Ae; Kim, Hyun Ok; Han, Kyou Sup

doi:10.1016/j.transci.2008.01.007

Cited by 21 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, filtration plasmapheresis is different from conventional plasmapheresis in that the replacement fluid is albumin rather than FFP. This can be advantageous given the relatively high rate of complications associated with FFP [9]. It has been reported that allergic reactions and anaphylatoid reactions are much less common when using albumin instead of FFP [9,10], and in fact, we experienced no allergic reactions related to the use of albumin.…”

Section: Discussionmentioning

confidence: 85%

“…This can be advantageous given the relatively high rate of complications associated with FFP [9]. It has been reported that allergic reactions and anaphylatoid reactions are much less common when using albumin instead of FFP [9,10], and in fact, we experienced no allergic reactions related to the use of albumin. In addition, albumin is easy to store and prepare in that it can be stored at room temperature and does not have to be thawed unlike FFP.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Clinical analysis of single filtration plasmapheresis using continuous renal replacement therapy machines in kidney transplantation

Lim

Kim

Jeong

et al. 2017

Kidney Res Clin Pract.

View full text Add to dashboard Cite

BackgroundPlasmapheresis has become an essential element of kidney transplantation (KT). In the present study, we report clinical outcomes of filtration plasmapheresis using continuous renal replacement therapy machines with a single filter for the first time in Korea.MethodsWe retrospectively analyzed six patients who underwent filtration plasmapheresis for KT in our center; plasmapheresis was performed using the Plasmaflex (Baxter®) with a TPE 2000 filter set (Baxter®) in our hemodialysis unit. Five percent albumin was used as the replacement fluid, and intravenous immunoglobulin G was administered after each plasmapheresis session. The target preoperative ABO isoagglutinin titer was less than 1:8.ResultsFiltration plasmapheresis was performed in four patients for ABO-incompatible KT, one for antibody-mediated rejection after KT, and the last one for positive T cell crossmatch. Altogether, 46 sessions of plasmapheresis were performed. ABO isoagglutinin titers successfully declined to or below the target level in all patients, and all patients successfully received KT with no significant antibody titer rebound. Acute antibody-mediated rejection and positive T cell crossmatch were well treated with filtration plasmapheresis, and no patient required fresh frozen plasma infusion for coagulopathy. There were one episode of hypotension and three of hypocalcemia. No patients experienced bleeding, infection, or allergic reaction.ConclusionFiltration plasmapheresis was effective and safe. Although our result is from a single center, our protocol appears to be promising.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 85%

Clinical analysis of single filtration plasmapheresis using continuous renal replacement therapy machines in kidney transplantation

Lim

Kim

Jeong

et al. 2017

Kidney Res Clin Pract.

View full text Add to dashboard Cite

show abstract

“…This is not surprising as both PLSs and PLTs account for the apheresis techniques that are most often applied in Germany [6]. Of note, our system will probably assess more SAEs than previously reported [13][14][15]23]. This is, at least in part, due to assessment of technical (e.g., disposable leakage) and donor characteristics typically associated with deferral from haemapheresis (e.g., blood count abnormalities).…”

Section: Discussionmentioning

confidence: 87%

“…The numbers of evaluated aphereses ranged from approximately 5,000-20,000 [12][13][14][15]18] to beyond 1 million [9,11]. The AE categories encompassed blood access injuries (BAI) or vasovagal reactions (VVR) as a single evaluation parameter in a few papers [16,[18][19][20], the combination of BAI, citrate toxicity (CT) and VVR in other studies [9,10,12,15,17,21,23] and occasionally a more comprehensive selection including BAI, CT, VVR, donor compliance (DC) problems and technical (apheresis machine-or apheresis disposable-related) events [11,13]. Further largely diverging parameters refer to the choice of the apheresis machines and the apheresis procedures.…”

Section: Introductionmentioning

confidence: 99%

“…Another very important point that impairs the comparability of the reported AE results was the long lasting absence of an internationally accepted standard for assessment and grading of AEs in blood donation. Consequently, 11 out of 14 groups developed own centre-specific systems for assessment and grading of AEs [10,11,[13][14][15][16][19][20][21][22][23]. The remaining groups adopted a standard that had been developed by a scientific society [12] or applied a national (French) standard for donor haemovigilance [9,17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Donor Safety in Haemapheresis: Development of an Internet-Based Registry for Comprehensive Assessment of Adverse Events from Healthy Donors

Heuft

Fischer

Weingand

et al. 2016

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Currently, there is an extensive but highly inconsistent body of literature regarding donor adverse events (AEs) in haemapheresis. As the reports diverge with respect to types and grading of AEs, apheresis procedures and machines, the range of haemapheresis-related AEs varies widely from about 0.03% to 6.6%. Methods: The German Society for Transfusion Medicine and Immunohaematology (DGTI) formed a ‘Haemapheresis Vigilance Working Party' (Arbeitsgemeinschaft Hämapheresevigilanz; AGHV) to create an on-line registry for comprehensive and comparable AE assessment with all available apheresis devices in all types of preparative haemapheresis: plasmapheresis (PLS), plateletpheresis (PLT), red blood cell apheresis, all kind of leukaphereses (autologous/allogeneic blood stem cell apheresis, granulocyte apheresis, lymphocyte/monocyte apheresis) and all possible types of multi-component apheresis. To ensure the comparability of the data, the AGHV adopted the ‘Standard for Surveillance of Complications Related to Blood Donation' from the International Society for Blood Transfusion in cooperation with the International Haemovigilance Network (IHN) and the American Association of Blood Banks for AE acquisition and automated evaluation. The registry is embedded in a prospective observational multi-centre study with a study period of 7 years. Results: A preliminary evaluation encompassed the time period from January, 2012 to December, 2015. During this time, the system proved to be safe and stable. Out of approximately 345,000 haemaphereses 16,477 AEs were reported (4.9%) from 20 participating centres. The majority of AEs occurred in PLSs (63%), followed by PLT (34.5%) and SC (2.2%). Blood access injuries (BAI) accounted for about 55% of the supplied AEs, whereas citrate toxicity symptoms, vasovagal reactions and technical events (e.g. disposable leakages, software failures) rather equally affected haemaphereses at 8-15%. Out of 12,348 finalized AEs, 8,759 (70.1%) were associated with a procedure-related break-off, with BAI being the prevailing cause (5,463/8,759; 62.4%). An automated centre- and procedure-specific AE evaluation according to the latest IHN standard and AGHV pre-settings is available within a few minutes. Conclusions: An on-line electronic platform for comprehensive assessment and centre-specific automated evaluation of AEs in haemaphereses has been developed and proved to be stable and safe over a period of 4 years.

show abstract

Establishing an institutional therapeutic apheresis registry

Mann

McCleskey

Marques

et al. 2016

J of Clinical Apheresis

View full text Add to dashboard Cite

Apheresis was first performed as a therapeutic procedure in the 1950s. The first national therapeutic apheresis (TA) registry was established in Canada in 1981 and other national registries followed, including two attempts at establishing an international TA registry. There is no national registry in the United States. Our large, academic, tertiary hospital has a very active TA service. We created a TA database to track all procedures performed by the apheresis service by transferring data from paper appointment logs and the electronic medical records into a Microsoft Access database. Retrospective data from each TA procedure performed at UAB from January 1, 2003 through December 31, 2012 were entered, including the type of procedure, indication, date, and patient demographics. Microsoft Excel was used for data analysis. During the 10-year period, our TA service treated 1,060 patients and performed 11,718 procedures. Of these patients, 70% received therapeutic plasma exchange (TPE), 21% received extracorporeal photopheresis (ECP), 4.5% received red cell exchange (RCE), 4.2% received leukocytapheresis, and 0.6% underwent platelet depletion. Among the procedures, 54% were TPEs, 44% were ECPs, 1.3% were RCEs, 0.5% were leukocytaphereses, and 0.1% were platelet depletions. According to the current literature, national and international TA use is underreported. We believe that the UAB TA registry provides useful information about TA practices in our region and can serve as a model for other institutions. Furthermore, data from multiple institutional registries can be used for clinical research to increase the available evidence for the role of TA in various conditions. J. Clin. Apheresis 31:516-522, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

Establishment of a national on-line registry for apheresis in Korea

Cited by 21 publications

References 20 publications

Clinical analysis of single filtration plasmapheresis using continuous renal replacement therapy machines in kidney transplantation

Clinical analysis of single filtration plasmapheresis using continuous renal replacement therapy machines in kidney transplantation

Donor Safety in Haemapheresis: Development of an Internet-Based Registry for Comprehensive Assessment of Adverse Events from Healthy Donors

Establishing an institutional therapeutic apheresis registry

Contact Info

Product

Resources

About